Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2610]

ESMO 2016: Greater patient selection may be needed for first line nivolumab to improve PFS in advanced lung cancer

ESMO 2016: Greater patient selection may be needed for first line nivolumab to improve PFS in advanced lung cancer

ESMO 2016: Ceritinib provides longer PFS than chemo in trial of ALK rearranged lung cancer treatment

ESMO 2016: Ceritinib provides longer PFS than chemo in trial of ALK rearranged lung cancer treatment

ESMO 2016: Pembrolizumab new option for first line treatment of patients with advanced lung cancer and high PD-L1 expression

ESMO 2016: Pembrolizumab new option for first line treatment of patients with advanced lung cancer and high PD-L1...

ESMO 2016: Significant survival gains with atezolizumab vs docetaxel for non-small-cell lung cancer

ESMO 2016: Significant survival gains with atezolizumab vs docetaxel for non-small-cell lung cancer

ESMO 2016: True burden of head and neck cancer in France underestimated by more than one-third

ESMO 2016: True burden of head and neck cancer in France underestimated by more than one-third

ESMO 2016: Neoadjuvant immunotherapy prior to surgery is safe and feasible in early lung cancer

ESMO 2016: Neoadjuvant immunotherapy prior to surgery is safe and feasible in early lung cancer

Scientists find lethal vulnerability in treatment-resistant lung cancer

Scientists find lethal vulnerability in treatment-resistant lung cancer

MicroRNA specifically kills cancer cells with common mutation

MicroRNA specifically kills cancer cells with common mutation

Bladder cancer research rife with new approaches

Bladder cancer research rife with new approaches

Chromosomal instability score may predict response to cancer treatment

Chromosomal instability score may predict response to cancer treatment

More from ecancer